Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.

A global view of the interplay between non-alcoholic fatty liver disease and diabetes

Stefan, Norbert, Cusi, Kenneth · 2022 · The Lancet Diabetes & Endocrinology

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular disease. The pathophysiology of NAFLD, particularly involving insulin resistance and subclinical inflammation, is not only closely linked to that of those NCDs but also to a severe course of the communicable disease COVID-19. Genetics alone cannot explain the large increase in the prevalence of NAFLD during the past 2 decades and the increase that is projected for the next decades. Impairment of glucose and lipid metabolic pathways, which has been propelled by the worldwide increase in the prevalence of obesity and type 2 diabetes, is most likely behind the increase in people with NAFLD. As the prevalence of NAFLD varies among subgroups of patients with diabetes and prediabetes identified by cluster analyses, stratification of people with diabetes and prediabetes by major pathological mechanistic pathways might improve the diagnosis of NAFLD and prediction of its progression. In this Review, we aim to understand how diabetes can affect the development of hepatic steatosis and its progression to advanced liver damage. First, we emphasise the extent to which NAFLD and diabetes jointly occur worldwide. Second, we address the major mechanisms that are involved in the pathogenesis of NAFLD and type 2 diabetes, and we discuss whether these mechanisms place NAFLD in an important position to better understand the pathogenesis of NCDs and communicable diseases, such as COVID-19. Third, we address whether this knowledge can be used for personalised treatment of NAFLD in the future. Finally, we discuss the current treatment strategies for people with type 2 diabetes and their effectiveness in treating the spectrum of hepatic diseases from simple steatosis to non-alcoholic steatohepatitis and hepatic fibrosis.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00003-1

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

1 retracted

Show all 127 references

Research works printed but not linked: 1

  1. Chen, 2020, Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus, PLoS One, 15

Cited by

See all 593

Metadata

Authors
Stefan, N., & Cusi, K.
Affiliations
  • Helmholtz Munich (DE)
  • University of Florida Health (US)
Corresponding author
Stefan, Norbert
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2022-04
Volume
10
Issue
4
Pages
284-296
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4212798162
Cited by
593
References
127
Citations by year
2026: 95 · 2025: 116 · 2024: 162 · 2023: 137 · 2022: 82
FWCI
19.79
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Site cant be reached (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Funders
  • Bundesministerium für Bildung und Forschung
  • Deutsche Forschungsgemeinschaft (STE 1096/1\u20133, KFO 114)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, type 2 diabetes, prediabetes, insulin resistance, hepatic steatosis, nonalcoholic steatohepatitis, liver fibrosis, COVID-19 pandemic, non-communicable diseases, obesity, NAFLD prevalence, NAFLD pathogenesis, personalized treatment
MeSH terms
COVID-19, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Liver, Prediabetic State, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A global view of the interplay between non-alcoholic fatty liver disease and diabetes. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00003-1
The paper
Stefan, N., & Cusi, K. (2022). A global view of the interplay between non-alcoholic fatty liver disease and diabetes. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00003-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.